A Phase II Stdy of ZD 1839 in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
OBJECTIVES: I. Determine the activity of ZD 1839 in patients with metastatic or recurrent
squamous cell carcinoma of the head and neck. II. Determine the effectiveness of this
regimen in these patients. III. Determine the toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study. Patients receive oral ZD 1839 once daily on days 1-28.
Treatment repeats every 28 days in the absence of disease progression or unacceptable
toxicity. Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 22-46 patients will be accrued for this study within 1-2
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Early response rates of ZD1839 in head and neck tumors
Everett Vokes, MD
University of Chicago
United States: Federal Government
|University of Chicago Cancer Research Center||Chicago, Illinois 60637|
|Loyola University Medical Center||Maywood, Illinois 60153|
|Ingalls Memorial Hospital||Harvey, Illinois 60426|
|Evanston Northwestern Health Care||Evanston, Illinois 60201|
|Louis A. Weiss Memorial Hospital||Chicago, Illinois 60640|
|Cancer Care Specialists of Central Illinois, S.C.||Decatur, Illinois 62526|
|Oncology/Hematology Associates of Central Illinois, P.C.||Peoria, Illinois 61602|
|Fort Wayne Medical Oncology and Hematology, Inc.||Fort Wayne, Indiana 46885-5099|
|Michiana Hematology/Oncology P.C.||South Bend, Indiana 46617|
|Oncology Care Associates, P.L.L.C.||Saint Joseph, Michigan 49085|
|Columbia LaGrange Memorial Hospital||LaGrange, Illinois 60525|